Timber Pharmaceuticals Reveals Commencement Of NYSE American Delisting Proceedings: Common Stock Expected To Begin Trading On OTC Market
Portfolio Pulse from Benzinga Newsdesk
Timber Pharmaceuticals announced the start of delisting proceedings from the NYSE American. Its common stock is expected to trade on the OTC market following the delisting.

November 29, 2023 | 10:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Timber Pharmaceuticals is beginning the process of delisting from the NYSE American, which will likely lead to its stock trading on the OTC market.
Delisting from a major exchange like the NYSE American generally reflects negatively on a company's financial health or compliance with listing standards. This can lead to decreased investor confidence and liquidity, often resulting in a negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100